Skip to main content
Top
Published in: Archives of Virology 3/2016

01-03-2016 | Brief Report

Immunoenhancement with flagellin as an adjuvant to whole-killed rabies vaccine in mice

Authors: Xing-xing Xiao, Yun Zhang, Ji-xing Liu, Qiao-lin Wei, Xiang-ping Yin

Published in: Archives of Virology | Issue 3/2016

Login to get access

Abstract

Vaccination is the most effective method for preventing rabies virus (RABV) infection in both humans and animals; however, no satisfactory vaccine has been developed for use worldwide. In the present study, we investigated the immunoadjuvant properties of Salmonella Typhimurium flagellin (FljB, FliC, and FljB’-FliC) to improve immune responses against the rabies vaccine (RV) and the protective efficacy of the whole-killed rabies vaccine (WKRV) with or without flagellins in BALB/c mice. We also compared the differences among the three flagellins in terms of immunoadjuvant properties to RV. FljB can cause the WKRV to induce stronger humoral and cellular immune responses than WKRV alone or WKRV with FliC or FljB’-FliC can. Mice immunized with WKRV and FljB produced higher levels of virus-neutralizing antibody (VNA) against RABV than those in the other groups did. Although mice in all treatment groups survived RABV challenge, the body weight loss in the group immunized with WKRV and FljB was lower than in the other groups. These results indicate that FljB is a promising adjuvant for use in the development of effective rabies vaccines.
Literature
1.
2.
go back to reference Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S (2013) Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31:1210–1216CrossRefPubMed Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S (2013) Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31:1210–1216CrossRefPubMed
3.
go back to reference Ben-Yedidia T, Arnon R (2007) Epitope-based vaccine against influenza. Expert Rev Vaccines 6:939–948CrossRefPubMed Ben-Yedidia T, Arnon R (2007) Epitope-based vaccine against influenza. Expert Rev Vaccines 6:939–948CrossRefPubMed
4.
go back to reference Chen Z, Zhou M, Gao X, Zhang G, Ren G, Gnanadurai CW, Fu ZF, He B (2013) A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein. J Virol 87:2986–2993PubMedCentralCrossRefPubMed Chen Z, Zhou M, Gao X, Zhang G, Ren G, Gnanadurai CW, Fu ZF, He B (2013) A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein. J Virol 87:2986–2993PubMedCentralCrossRefPubMed
5.
go back to reference Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J (2004) Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72:2810–2816PubMedCentralCrossRefPubMed Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J (2004) Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72:2810–2816PubMedCentralCrossRefPubMed
6.
go back to reference Dietzschold B, Schnell M, Koprowski H (2005) Pathogenesis of rabies. Curr Top Microbiol Immunol 292:45–56PubMed Dietzschold B, Schnell M, Koprowski H (2005) Pathogenesis of rabies. Curr Top Microbiol Immunol 292:45–56PubMed
9.
go back to reference Ghose C, Verhagen JM, Chen X, Yu J, Huang Y, Chenesseau O, Kelly CP, Ho DD (2013) Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease. Infect Immun 81:2190–2196PubMedCentralCrossRefPubMed Ghose C, Verhagen JM, Chen X, Yu J, Huang Y, Chenesseau O, Kelly CP, Ho DD (2013) Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease. Infect Immun 81:2190–2196PubMedCentralCrossRefPubMed
10.
go back to reference Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103CrossRefPubMed Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103CrossRefPubMed
11.
go back to reference Honko AN, Sriranganathan N, Lees CJ, Mizel SB (2006) Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74:1113–1120PubMedCentralCrossRefPubMed Honko AN, Sriranganathan N, Lees CJ, Mizel SB (2006) Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74:1113–1120PubMedCentralCrossRefPubMed
12.
go back to reference Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ (2007) Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763–775CrossRefPubMed Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ (2007) Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763–775CrossRefPubMed
13.
go back to reference Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu X, Noah D, Hou F, Weaver B, Tussey L (2012) Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30:6833–6838CrossRefPubMed Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu X, Noah D, Hou F, Weaver B, Tussey L (2012) Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30:6833–6838CrossRefPubMed
14.
go back to reference Liu Y, Zhang S, Zhang F, Hu R (2012) Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines. Int J Biol Macromol 50:598–602CrossRefPubMed Liu Y, Zhang S, Zhang F, Hu R (2012) Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines. Int J Biol Macromol 50:598–602CrossRefPubMed
15.
go back to reference Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF, Advisory Committee on Immunization Practices Centers for Disease C, Prevention, (2008) Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 57:1–28PubMed Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF, Advisory Committee on Immunization Practices Centers for Disease C, Prevention, (2008) Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 57:1–28PubMed
17.
go back to reference McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ (2007) A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195:1607–1617CrossRefPubMed McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ (2007) A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195:1607–1617CrossRefPubMed
18.
go back to reference McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169:3914–3919CrossRefPubMed McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169:3914–3919CrossRefPubMed
19.
go back to reference Shen CF, Lanthier S, Jacob D, Montes J, Beath A, Beresford A, Kamen A (2012) Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Vaccine 30:300–306CrossRefPubMed Shen CF, Lanthier S, Jacob D, Montes J, Beath A, Beresford A, Kamen A (2012) Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Vaccine 30:300–306CrossRefPubMed
20.
go back to reference Shen E, Li L, Li L, Feng L, Lu L, Yao Z, Lin H, Wu C (2007) PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell Mol Immunol 4:113–120PubMed Shen E, Li L, Li L, Feng L, Lu L, Yao Z, Lin H, Wu C (2007) PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell Mol Immunol 4:113–120PubMed
21.
go back to reference Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW (2010) Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28:4103–4112PubMedCentralCrossRefPubMed Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW (2010) Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28:4103–4112PubMedCentralCrossRefPubMed
22.
go back to reference Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4:1247–1253CrossRefPubMed Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4:1247–1253CrossRefPubMed
23.
go back to reference van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27:49–55CrossRefPubMed van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27:49–55CrossRefPubMed
24.
go back to reference Wang BZ, Gill HS, Kang SM, Wang L, Wang YC, Vassilieva EV, Compans RW (2012) Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol 19:1119–1125PubMedCentralCrossRefPubMed Wang BZ, Gill HS, Kang SM, Wang L, Wang YC, Vassilieva EV, Compans RW (2012) Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol 19:1119–1125PubMedCentralCrossRefPubMed
25.
go back to reference WHO (2005) First report of the WHO Expert Committee on Rabies. Technical Report Series 931. WHO, Geneva WHO (2005) First report of the WHO Expert Committee on Rabies. Technical Report Series 931. WHO, Geneva
26.
go back to reference Zieg J, Silverman M, Hilmen M, Simon M (1977) Recombinational switch for gene expression. Science 196:170–172CrossRefPubMed Zieg J, Silverman M, Hilmen M, Simon M (1977) Recombinational switch for gene expression. Science 196:170–172CrossRefPubMed
Metadata
Title
Immunoenhancement with flagellin as an adjuvant to whole-killed rabies vaccine in mice
Authors
Xing-xing Xiao
Yun Zhang
Ji-xing Liu
Qiao-lin Wei
Xiang-ping Yin
Publication date
01-03-2016
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 3/2016
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-015-2704-8

Other articles of this Issue 3/2016

Archives of Virology 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.